| Glenn Stephen Coats, MD | |
|
5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818-9701 | |
| (260) 432-1568 | |
| (260) 432-4969 |
| Full Name | Glenn Stephen Coats |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 5001 Us Highway 30 W Ste D, Fort Wayne, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215220363 | NPI | - | NPPES |
| 201356910 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 01076627A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lutheran Hospital Of Indiana | Fort wayne, IN | Hospital |
| Marion General Hospital | Marion, IN | Hospital |
| Maine Medical Center | Portland, ME | Hospital |
| Henry County Memorial Hospital | New castle, IN | Hospital |
| Kosciusko Community Hospital | Warsaw, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Radiology Pc | 0143295410 | 75 |
| X-ray Physicians Of Shelbyville Pc | 2264420215 | 44 |
| Henry County Memorial Hospital | 6002724085 | 112 |
| Decatur County Memorial Hospital | 7315837671 | 66 |
| Spectrum Healthcare Partners Pa | 7618871245 | 265 |
| Summit Radiology Pc | 0143295410 | 75 |
| Summit Radiology Pc | 0143295410 | 75 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Henry County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891570537 PECOS PAC ID: 6002724085 Enrollment ID: O20031121000221 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Decatur County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952300477 PECOS PAC ID: 7315837671 Enrollment ID: O20040318001580 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | X-ray Physicians Of Shelbyville Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144351347 PECOS PAC ID: 2264420215 Enrollment ID: O20040506000325 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Summit Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073584587 PECOS PAC ID: 0143295410 Enrollment ID: O20040831000152 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710993159 PECOS PAC ID: 7618871245 Enrollment ID: O20131127001392 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Riverside Radiology And Interventional Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093718496 PECOS PAC ID: 8729976964 Enrollment ID: O20230426000333 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Entity Name | Gainesville Radiology Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922037605 PECOS PAC ID: 9335046382 Enrollment ID: O20240311003035 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Glenn Stephen Coats, MD Po Box 80070, Fort Wayne, IN 46898-0070 Ph: (260) 432-1568 | Glenn Stephen Coats, MD 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818-9701 Ph: (260) 432-1568 |
News Archive
The break neck pace of genomic discoveries has ushered in a new problem in the delivery of personalized medicine: comprehensive and consistent data reporting that will improve health information technologies for better patient care.
New research by a multidisciplinary collaboration between the Queen Mary University of London, Asthma UK Centre for Applied Research (AUKCAR) the University of Edinburgh, University of Nottingham, University of Cambridge and charity Asthma UK, published in the Journal of Medical Internet Research, looks at the characteristics of superusers who are actively engaged in the Asthma UK online community and Facebook group to help healthcare professionals better understand the role they play in supporting the management of long-term conditions.
Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.
Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD).
› Verified 1 days ago
Dr. Benjamin Jon Moreno, MD, PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr Ste 110, Fort Wayne, IN 46845 Phone: 260-469-6602 Fax: 260-484-5919 | |
Dr. Andre Byard Stovall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818 Phone: 260-432-1568 Fax: 260-432-4969 | |
Dr. Christopher Edson Carrel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr, Fort Wayne, IN 46845 Phone: 604-696-6022 Fax: 616-363-7290 | |
Dr. Gregg R Mattison, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3707 New Vision Drive, Fort Wayne, IN 46895 Phone: 260-471-9466 Fax: 260-484-5919 | |
Christopher M Wing, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-471-9466 Fax: 260-484-5919 | |
Dr. Ahdy Messiha, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7950 W Jefferson Blvd, Fort Wayne, IN 46804 Phone: 260-432-1568 Fax: 260-432-4969 | |
Vivek K. Sharma, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818 Phone: 260-432-1568 Fax: 260-432-4969 |